Latest News

Crescent Diagnostics appoints Barry Clare as Chairman.

Dublin, Ireland. 9 September 2013. … Crescent Diagnostics Ltd (“Crescent”), a Seroba Kernel portfolio company and a developer of novel tests for predicting osteoporotic fracture risk, is pleased to announce the appointment of Barry Clare as Chairman. Barry was previously a main board director at The Boots Company PLC, and is currently CEO and Chairman of Healthcare Brands...


Apica Cardiovascular has received CE Mark Approval

Dublin, September 4th, 2013 – Galway based, Apica Cardiovascular, has received CE Mark Approval for its platform Access, Stabilisation, and Closure (ASC™) system that allows for the delivery of aortic and mitral valves through the chest wall and apex of the beating heart. The ASC system is a breakthrough enabling platform technology that can be used by surgeons, in...


Opsona Therapeutics Limited raises an additional €3 million.

Opsona Therapeutics Limited raises an additional €3 million (US $4 million) from Omnes Capital in Series C extension, resulting in a total financing round of € 36 million (US $48.6 million) October 2nd, 2013, Dublin, Ireland. – Opsona Therapeutics Limited (Opsona), the innate immune drug development company and portfolio company of Seroba Kernel Life...


< back to home page